Opening soon. Stay in the loop

goodmorrowJoin the opening list

Read beyond the headline.

The original documents, the discussion behind them, and the questions that remain.

These primary sources were opened and checked on September 28, 2026. They support the explanations on this page. The broader treatment library remains draft educational content pending documented clinical review.

FDA meeting record

The July 2026 peptide discussion

The agenda, documents, and recordings for the July 23–24 Pharmacy Compounding Advisory Committee meeting. Committee recommendations are nonbinding.

This meeting page does not establish the current availability of a treatment.
FDA questions and answers

What compounding means

The FDA explains how compounded medicines differ from approved medicines, why some patients need them, and the risks involved.

Compounded drugs do not undergo FDA premarket review for safety, effectiveness, and quality.
FDA scientific presentation

Read the scientific review

The July 23 meeting slides explain the FDA's evaluation framework and present its assessments of the compounds on that day's agenda.

A dated scientific assessment should be read alongside subsequent FDA actions.

For the full peptide discussion, watch the July 23, 2026 committee meeting. This is a long-form public record.

Three questions to bring to a claim.

Was the study in people? Did it examine the same formulation and use being discussed? Were the results meaningful enough to guide a treatment decision?

Those questions help separate an interesting finding from a conclusion you can use. Your clinician also needs to consider your medical history and the risks specific to you.

About our sources and review.

Guides link to their references near the top and list them in full below the article. Source labels distinguish FDA documents, research publications, manufacturer information, and secondary reporting.

A publication date does not mean a clinician reviewed the page. An individual review is attributed only when it has been recorded and the reviewer can be publicly identified. Read the editorial policy.

Explore the peptide guides